Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged =18 years) (pIn the Phase 2 trial, 42% of Tinlarebant-treated subjects (5 out of 12) did not develop atrophic retinal lesions during the 24-month treatment periodEnrollment of a pivotal global Phase 3 trial of Tinlarebant in adolescent STGD1 subjects (“DRAGON”) has been completed with 104 subjects across 11 countriesInterim data from the “DRAGON” trial expected in 4Q 2024Dosed first subject in pivotal global Phase 3 trial of Tinalrebant in GA subjects (“PHOENIX”) and received approval to initiate PHOENIX trial in eight countriesAs of D
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingGlobeNewswire
- Belite Bio Announces $25 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Belite Bio Announces $25 Million Registered Direct OfferingGlobeNewswire
- Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsightPR Newswire
BLTE
Earnings
- 3/11/24 - Beat
BLTE
Sec Filings
- 4/29/24 - Form 424B5
- 4/26/24 - Form 6-K
- 3/22/24 - Form 144
- BLTE's page on the SEC website